drugset / Trial / NCT07242300

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .

NCT07242300

Phase 3 Not yet recruiting 207 enrolled JHM BioPharma (Tonghua) Co. , Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase III clinical study to evaluate the efficacy and safety of recombinant botulinum toxin type A(Eveotox)in adult patients with upper limb spasticity. The purpose of this study was to observe efficacy and safety of Eveotox compared with placebo in adult patients with upper limb spasticity.

Timeline

Start
2026-01
Primary completion
2026-12
Completion
2028-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eveotox Protein / enzyme biologic